Inogen (NASDAQ: INGN) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitabiliy.
Institutional and Insider Ownership
63.9% of Bio-Rad Laboratories shares are held by institutional investors. 5.3% of Inogen shares are held by company insiders. Comparatively, 28.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Inogen and Bio-Rad Laboratories’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Inogen | $212.34 million | 9.15 | $35.35 million | $0.93 | 101.53 |
| Bio-Rad Laboratories | $2.10 billion | 3.29 | $271.79 million | $0.94 | 248.44 |
Bio-Rad Laboratories has higher revenue and earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Inogen and Bio-Rad Laboratories, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inogen | 0 | 2 | 1 | 1 | 2.75 |
| Bio-Rad Laboratories | 0 | 0 | 4 | 0 | 3.00 |
Inogen currently has a consensus target price of $91.00, indicating a potential downside of 3.62%. Bio-Rad Laboratories has a consensus target price of $225.00, indicating a potential downside of 3.65%. Given Inogen’s higher possible upside, research analysts clearly believe Inogen is more favorable than Bio-Rad Laboratories.
Risk & Volatility
Inogen has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Profitability
This table compares Inogen and Bio-Rad Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inogen | 9.32% | 11.67% | 9.66% |
| Bio-Rad Laboratories | 1.35% | 3.23% | 2.19% |
Summary
Bio-Rad Laboratories beats Inogen on 8 of the 15 factors compared between the two stocks.
Inogen Company Profile
Inogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
